Product launch

Bevacizumab Injection(Boyounuo®

Boyounuo is a biosimilar approved by the National Medical Products Administration (NMPA) in accordance with Technical Guidelines for Evaluation on Similarities and Extrapolation of Indications of Biosimilars promulgated in February 2021.


  • MCRC: Fluoropyrimidine-based chemotherapy combined with Bevacizumab applies to treatment of MCRC.
  • Advanced metastatic or recurrent NSCLC: As a first-line therapy for unresectable, advanced, recurrent or metastatic NSCLC, bevacizumab is administered in combination with platinum-based chemotherapy, followed by bevacizumab as a single agent.
  • Recurrent glioblastoma
  • Ovarian cancer and cervical cancer

(This product is a prescription drug, please take this drug with doctor’s prescription and under doctor’s instruction)

How does Bevacizumab work

Different from chemotherapy that directly attack cancer cells, Bevacizumab functions by blocking blood supply to a tumor, so as to inhibit its growth.

Vascular endothelial growth factor (VEGF) promotes angiogenesis by inducing proliferation of endothelial cells. With overexpression of VEGFs in diverse tumors, Bevacizumab blocks combination of free VEGFs and relevant receptors to inhibit neoplastic neovascularization. As tumor gets diminishing support in nutrition, it will be restrained from growth eventually.

Key to anti-angiogenesis therapy - continuous inhibition of VEGF pathways

Crucial factor for regulating angiogenesis - interaction of VEGC ligands and receptors

Bevacizumab targets VEGF and sustainably inhibits tumor growth

1. Rini BI, Small EJ. J Clin Oncol 2005;23:1028-1043.
2. Ruba S. Darweesh, et al. International Journal of Nanomedicine. 2019,14:7643-7663.

Contact us

No.39 Keji Avenue High-Tech Industrial Development Zone Yantai, Shandong Province, China


Follow me